NewAmsterdam Pharma Company N.V.
NAMS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $45,563 | $14,090 | $102,694 | $0 |
| % Growth | 223.4% | -86.3% | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $45,563 | $14,090 | $102,694 | $0 |
| % Margin | 100% | 100% | 100% | – |
| R&D Expenses | $151,406 | $159,424 | $86,744 | $28,974 |
| G&A Expenses | $70,446 | $37,633 | $19,507 | $4,700 |
| SG&A Expenses | $70,446 | $37,633 | $19,507 | $5,677 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $977 |
| Other Operating Expenses | $0 | $0 | $0 | $326 |
| Operating Expenses | $221,852 | $197,057 | $106,251 | $34,977 |
| Operating Income | -$176,289 | -$182,967 | -$3,557 | -$34,977 |
| % Margin | -386.9% | -1,298.6% | -3.5% | – |
| Other Income/Exp. Net | -$65,310 | $6,057 | -$19,077 | -$6,808 |
| Pre-Tax Income | -$241,599 | -$176,910 | -$22,634 | -$41,785 |
| Tax Expense | -$1 | $27 | $0 | $0 |
| Net Income | -$241,598 | -$176,937 | -$22,634 | -$41,785 |
| % Margin | -530.3% | -1,255.8% | -22% | – |
| EPS | -2.56 | -2.15 | -1.11 | -3.34 |
| % Growth | -19.1% | -93.7% | 66.8% | – |
| EPS Diluted | -2.56 | -2.15 | -1.11 | -3.34 |
| Weighted Avg Shares Out | 94,358 | 82,160 | 18,966 | 17,751 |
| Weighted Avg Shares Out Dil | 94,358 | 82,162 | 18,966 | 17,751 |
| Supplemental Information | – | – | – | – |
| Interest Income | $16,881 | $10,220 | $0 | $0 |
| Interest Expense | $0 | $6,799 | $287 | $411 |
| Depreciation & Amortization | $113 | $49 | $9 | $5 |
| EBITDA | -$241,486 | -$176,861 | -$22,338 | -$41,369 |
| % Margin | -530% | -1,255.2% | -21.8% | – |